An AI-designed genetic-medicine company

Durable genetic medicines, designed by AI.

Months of therapeutic protein from a single, thermostable injection — durable, multi-payload, and redosable.

Our thesis
The hard part isn't the gene — it's expressing enough of it, for long enough. Eyam uses AI to design the payload and engineer the best way to express it, so a single dose produces therapeutic protein at therapeutic levels, for months.
The system

One system. From code to cure.

Two parts work as one. Jennerator AI designs the payload; Gemini self-amplifying DNA (saDNA) expresses it in the body — durable protein from a single, thermostable dose.

01 — DESIGN

Engineer the payload

Jennerator AI designs and optimizes the genetic payload — one protein or many — for maximum expression and durability.

02 — EXPRESS

One simple dose

Gemini self-amplifying DNA enters cells and directs sustained production of the encoded protein or antibody. Thermostable; carrier-optional.

03 — SUSTAIN

Months of expression

The body produces therapeutic protein at therapeutic levels — for months, from a single dose.

What sets the platform apart

Four advantages, one platform.

Durable

Therapeutic protein for months — from a single, thermostable dose.

Multi-payload

One construct expresses a single protein or several at once.

Redosable

Non-viral and carrier-free, so a dose can be repeated as treatment requires.

Carrier-free

No lipid nanoparticle, no viral vector — naked and room-temperature stable.

Explore the platform →

Peer-reviewed

Nature Communications (2025)

Validated across species

Replicated across multiple preclinical species; non-human primate studies underway.

Global health

Backed by some of the most consequential global-health organizations in the world.

Why Eyam

Named for a village that chose to protect others.

In 1665, the village of Eyam sealed itself off to stop the plague from spreading — hundreds died within its walls so that their neighbors would live. That choice is our mission: to confront disease with courage, and to make durable medicine that reaches everyone it can — far beyond the walls of a major hospital.

Let's build the next generation of genetic medicines.

Eyam partners with pharmaceutical and global-health leaders through feasibility studies, platform licenses, and co-development.

Start a conversation →
"Designed by AI. Expressed by the body. Built to last."